Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Autor: Simon Warburton, Jasmin Bahlo, Eugen Tausch, Sebastian Böttcher, Kirsten Fischer, Javier López, Thomas J. Kipps, Michael Hallek, Lukas Frenzel, Matthias Ritgen, Valentin Goede, Othman Al-Sawaf, Sue Robinson, Anna-Maria Fink, Jacque J.M. Van Dongen, Anton W. Langerak, Stephen Opat, Kathryn Humphrey, Clemens M. Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Mark Dixon, Carolyn Owen, Rod A. Humerickhouse, Till Seiler, Robert Weinkove, Mehrdad Mobasher

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blood, 129(19), 2702-2705. American Society of Hematology

To the editor: In chronic lymphocytic leukemia (CLL), the median age at diagnosis is 72 years, and most patients requiring therapy have coexisting medical conditions. Venetoclax is a potent BH3-mimetic compound that selectively antagonizes BCL-2 and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc05c7b1b81cb997630e4809873e0a7
https://saludmadrid.ibai.com/handle/20.500.12530/32342